Cost of Treatment for Cervical Cancer in India.

Cost of Treatment for Cervical Cancer in India. Asian Pac J Cancer Prev. 2020 Sep 01;21(9):2639-2646 Authors: Singh MP, Chauhan AS, Rai B, Ghoshal S, Prinja S Abstract INTRODUCTION: Cervical cancer is a major public health problem in India leading to high economic burden, which is disproportionately borne by the patients as out-of-pocket expenditure (OOPE). Several publicly financed health insurance schemes (PFHIs) in India cover the treatment for cervical cancer. However, the provider payment rates for health benefit packages (HBP) under these PFHIs are not based on scientific evidence. We undertook this study to estimate the cost of services provided for treatment of cervical cancer and  cost of the package of care for cervical cancer in India. METHODS: The study was undertaken at a large public tertiary hospital in North India. The health system cost was assessed using a mixed micro-costing approach. The data were collected for all the resources utilized during service delivery for cervical cancer patients. To evaluate the OOPE, randomly selected 248 patients were interviewed following the cost of illness approach. Logistic regression was used to assess the factors associated with catastrophic health expenditure (CHE). RESULTS: Health system cost for different cervical cancer treatment modalities i.e. radiotherapy, brachytherapy, chemotherapy and surgery, ranges from INR 19,494 to 41,388 (USD 291 - 617). Furthermore, patients spent INR 4,0...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research

Related Links:

In patients with locally advanced cervical and endometrial cancer treated with combination chemotherapy, external beam radiation (EBRT) and brachytherapy, ureteral strictures are a rare though potentially severe toxicity. Dosimetric constraints have yet to be defined for these adjacent organs at risk.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Regular audits are a key component to a quality radiation treatment program. In an effort to understand current practice and plan for future state we performed an outcomes audit of our locally advanced cervix cancer patients treated with concurrent chemotherapy, external beam radiation therapy and brachytherapy. Our objective was to determine treatment outcomes and late toxicity
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Source Type: research
Clear cell adenocarcinoma of the cervix (CCAC) with genitourinary malformations is rare. Here, we report a case of CCAC in uterus didelphys (UD) associated with unilateral renal agenesis (URA) that was treated with intensity-modulated radiotherapy (IMRT) and high-dose rate intracavitary brachytherapy (HDR-ICBT). We also retrospectively reviewed the medical records of CCAC cases with genitourinary malformations treated at the National Cancer Center/Cancer Hospital (Beijing, China) between December 2006 and June 2017. Eight cases of this rare condition were identified by pathologic diagnosis. Seven patients received surgical...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: Early prediction of response to concurrent chemoradiotherapy (cCRT) could aid to further optimize treatment regimens for locally advanced cervical cancer (LACC) in the future. PURPOSE: To explore whether quantitative parameters from baseline (pre-therapy) magnetic resonance imaging (MRI) and FDG-PET/computed tomography (CT) have potential as predictors of early response to cCRT. MATERIAL AND METHODS: Forty-six patients with LACC undergoing cCRT after staging with FDG-PET/CT and MRI were retrospectively analyzed. Primary tumor volumes were delineated on FDG-PET/CT, T2-weighted (T2W)-M...
Source: Acta Radiologica - Category: Radiology Authors: Tags: Acta Radiol Source Type: research
Conclusions: Unlike past results, gemcitabine and cisplatin appear to be tolerable, efficient and feasible when combined with conformal radiotherapy.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
(American Society for Radiation Oncology) A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline--ASTRO's first for cervical cancer--outlines indications and best practices for external beam radiation therapy and brachytherapy in the postoperative and definitive settings. Recommendations also address other treatments including chemotherapy and surgery when used in combination with radiation. The guideline is published online in Practical Radiation Oncology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In the treatment of locally advanced cervical cancer (LACC) patients, the current treatment of choice is the administration of external beam radiotherapy (EBRT) with concomitant chemotherapy and image-guided adaptive brachytherapy. Research has shown that this patient group suffers from a variety of side effects caused by the treatment. Patients report, among others, gastrointestinal (GI) toxicity, genitourinary (GU) toxicity and overall decrease in quality of life (QoL) in both the acute and late phase after treatment [1].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
The standard of care for women with unresectable cervical cancer includes external beam radiotherapy (EBRT) with chemotherapy followed by a brachytherapy (BT) boost [1]. EBRT which treats the pelvis and adjacent nodal regions provides approximately 50% of the total dose. BT provides the remaining course of radiation to destroy the residual tumor cells. Recent advances in magnetic resonance image (MRI) guided BT have significantly improved local control: 95 –100% in limited stages (FIGO IB-IIB) and 85–90% in more advanced stages [2].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
Objective: Apatinib mesylate is a novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which has exhibited good safety and efficacy in several types of solid tumors. The present study aimed to assess the clinical efficacy and safety of apatinib combined with chemotherapy and concurrent chemo-brachytherapy (CCBT) in patients with recurrent and advanced cervical cancer. Methods: A total of 52 patients with first diagnosed recurrent or untreated International Federation of Gynecology and Obstetrics stage IVB cervical cancer admitted at Shandong Cancer Hospital and Institute between July 2016 and May 2...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
CONCLUSIONS: HT boost treatment showed comparable disease outcomes with those observed with conventional BT in patients with advanced cervical cancer. HT could be a complementary boost protocol as a single modality or hybrid with BT in selected patients. Further studies with longer follow-up periods are warranted to confirm long-term outcomes. PMID: 32026658 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Health Insurance | India Health | Insurance | International Medicine & Public Health | Study